Endocrine Abstracts

To determine a correlation between Vitamin D, GH, IGF1 and cardiovascular risk we enrolled. 41 GHD patients (22 M, 19 F, age 18–84 years) and 41 controls. In all we determined: anthropometric parameters, blood pressure (BP), lipid and glucose profile, PTH, 25-OH-vitamin D, GH peak after GHRH+ARG, IGF1. Metabolic syndrome (MS) was evaluated by the IDF criteria.

The vitamin D were lower in patients than in controls (21.3±12.3 vs 28.2±9.4, P=0.006). A deficiency of vitamin D (<20 ng/ml) was found in 51 vs 14.6% (P=0.000), insufficiency (20–30 ng/ml) in 26.8 vs 41.4% (P=0.27) and normal vitamin D (>30 ng/dl) in 21.9 vs 43.9% (P=0.06) respectively in patients and controls. The prevalence of dyslipidemia was 51.2 vs 12.1% (P=0.09), DM was 7.3 vs 17% (P=0.292) of hypertension was 44 vs 22% (P=0.06), MS was 17 vs 14.6% (P=0.957) respectively in patients and controls. In both groups there was a significant correlation between IGF1, age, vitamin D and SBP. At the multiple regression, the greater predictor of high values of SBP were IGF1 (t=−2.69, P=0.011, t=−0.18, P=0.018 respectively). At logistic regression only in patients we found a significant association between IGF1 and vitamin D deficiency and dyslipidemia and hypertension, but not with DM. The MS was significantly associated only with vitamin D. At the multiple logistic regression, vitamin D was associated with dyslipidemia and hypertension.

In GHD hypopituitaric patients the vitamin D is more associated with cardiovascular risk factors. Thus, it can be assumed that the vitamin D deficiency may represent an additional risk factor to the already known effects of hypopituitarism for cardiovascular diseases.